Jun 16, 2022 / 12:00PM GMT
David S. Zaccardelli - Verona Pharma plc - President, CEO & Executive Director
Good morning, everyone, and welcome to Verona Pharma R&D Day. It's a pleasure to be here in person after a couple of years and see everybody on this rainy New York Day, but welcome to you. Welcome to everybody on the webcast as well.
I'm Dave Zaccardelli, CEO of Verona Pharma. And what we plan to do today is spend some -- just a few minutes grounding us in a presentation on ensifentrine but, more importantly, have the opportunity to hear from 2 amazing physicians, treaters of COPD and KOLs. And very happy to have Dr. Igor Barjaktarevic with us today as well as Dr. Jill Ohar. And you won't have to hear too much from me, but we'll spend much of the time hearing from them and their views on ensifentrine.
So with that, I just want to spend a few moments on having everyone really understand the landscape of the COPD with regard to treatments. Really, the takeaway message on the slides is while there appears to be a lot of medications available for (inaudible) with the inhaled route of administration for
Verona Pharma PLC KOL event for analysts and investors Call Transcript
Jun 16, 2022
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers